Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
about
Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Immunization with recombinantly expressed glycan antigens from Schistosoma mansoni induces glycan-specific antibodies against the parasite.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerRecent advances in the development of breast cancer vaccines.The adjuvant effects of high-molecule-weight polysaccharides purified from Antrodia cinnamomea on dendritic cell function and DNA vaccines.Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope.Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccineTumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancerAnti-HER2/Neu passive-aggressive immunotherapy.Emerging immunotherapy strategies in breast cancer.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Design of Polyepitope DNA Vaccine against Breast Carcinoma Cells and Analysis of Its Expression in Dendritic Cells.Specific immunotherapy in ovarian cancer: a systematic review.Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.Receptor tyrosine kinases in carcinogenesis.Treating breast cancer with cell-based approaches: an overview.Meeting report VLPNPV: Session 5: Plant based technology.Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Present status and future perspective of peptide-based vaccine therapy for urological cancer.Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.Mechanisms of immune evasion in breast cancer.
P2860
Q33587034-0812AB38-7A0F-4FC3-83B9-D9344034DEEAQ33684607-EF14536C-6B6D-4879-BB45-57F188C64A36Q34268618-8A34FE97-FF71-4D10-A9D7-BA193F82A857Q34379303-14E67465-7967-4A89-9ABA-C97960FB4DCCQ35130229-C78C4CCF-91B3-45F9-8955-840CC3E63643Q35214496-A11CD192-CED4-464A-8DB3-E0BFB1E94B49Q36777133-41CD6E86-FC51-4A6E-9D81-532962FFF91BQ36797398-7024495B-D7F0-469F-A6CF-0DEFD2D8187BQ37289389-0C58258B-257E-4608-9CF7-EA05ECE2D508Q37323046-1DA5876C-D012-405C-97CC-FEE8F64D7FE3Q37605244-173291E3-762C-4FFE-9AD9-75729FC8CFD9Q38184650-B990E7B3-7BA7-4B25-8442-BA807396CE31Q38215394-66ACB4F7-81B6-4C1E-9823-D69CB8E9795AQ38244698-63E4DFDD-7AC4-4F7B-8F14-35D325802073Q38293525-B0F6BF64-7160-4664-BF8D-2614E812D6F4Q38301236-B1EE5757-2DA2-4B5E-A0A3-6F641A2BF7D0Q38447992-897A7D1E-6C11-4606-B1B2-E28FD44D461FQ38791070-A79DDD34-F18E-4E55-9A6F-BDB7C2B29E63Q38948893-80216BDD-1AAC-46DC-A605-75683BE58777Q38964264-EBA93C74-35E8-45E0-86D4-3DBFE19D1E86Q39024002-5386126E-21A3-4DB6-AB71-C64447F2BC1CQ39448180-35495641-B420-4D57-8FEE-83CE578A51DFQ42346870-B523BDEB-5175-44D2-BCAB-4D5BAB5F193EQ46388405-2795D81E-7E5F-4604-9E30-E4E9AE5A1AA6Q47725715-D8CAD2BE-836F-423A-B368-CBFE55F639FAQ48182026-01869FB4-FC24-4C80-B5C5-520F1B9AEFF1Q49378999-5E56CC0A-FB3E-4D7F-B0AB-114EDD521321Q54252199-C39FEDF5-485E-4654-AF52-648081C862CCQ55347716-CF564B26-32A5-4C75-8246-CF62C88AF0A7
P2860
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Active immunotherapy in HER2 o ...... tatus and future perspectives.
@en
type
label
Active immunotherapy in HER2 o ...... tatus and future perspectives.
@en
prefLabel
Active immunotherapy in HER2 o ...... tatus and future perspectives.
@en
P2860
P50
P356
P1433
P1476
Active immunotherapy in HER2 o ...... status and future perspectives
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDT133
P577
2013-04-12T00:00:00Z